The 4 most recent market catalysts affecting $PTHS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 31, 2026
Corporate Catalyst
Bullish
Impact 95
Pelthos Therapeutics to Merge with Castle Creek Biosciences
Pelthos Therapeutics is acquiring Castle Creek Biosciences in an all-stock deal, with Castle Creek stockholders receiving 5.2 million shares of Pelthos common stock, representing a…
Oct 6, 2026
Corporate Catalyst
Bullish
Impact 75
Pelthos Signs Agreement To Open Access To ZELSUVMI
The agreement to open access to ZELSUVMI is a direct corporate catalyst for Pelthos, indicating a strategic move to expand its market reach. This could lead to significant revenue …
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 55
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64
Oppenheimer analyst Jeff Jones has maintained an 'Outperform' rating on Pelthos Therapeutics (PTHS), signaling continued confidence in the company's long-term prospects. However, t…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
Pelthos Therapeutics Q2 EPS $(6.62) Misses $(3.05) Estimate, Sales $15.603M Beat $15.273M Estimate
Pelthos Therapeutics (PTHS) announced its Q2 earnings, revealing a substantial miss on EPS expectations, with reported losses of $(6.62) against an estimated $(3.05). This 117.05% …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.